Molecular Pharmacology & Therapeutics (MPaT) graduate program

Graduate training in pharmacology has a proud history at the University of Minnesota (UMN). More than 350 students have earned PhD degrees in Pharmacology at UMN since the first was awarded in 1924. Our alumni have led efforts in academia and industry resulting in the discovery and/or development of many prominent drugs in use today including the angiotensin receptor blocker losartan/Cozaar and the direct oral anti-coagulant apixaban/Eliquis, the cholesterol absorption inhibitor ezetimibe (Zetia) and its statin combination Vytorin, the Class III anti-arrhythmic drug ibutilide/Corvert, the anti-platelet GPIIB/IIIA antagonist tirofiban/Aggrastat, the anti-depressant sertraline/Zoloft, the analgesic tramadol (ConZip), the anti-seizure medication topiramate/Topamax, and the prostate cancer drug apalutamide/Erleada. Louis Ignarro (class of 1966) received the 1998 Nobel Prize in Physiology or Medicine for showing that nitric oxide is the gaseous second messenger that promotes vasodilation. We are proud of our alumni and the positive impacts they make in science and medicine.

The Molecular Pharmacology & Therapeutics (MPaT) graduate program offers MS and PhD degree programs, and participates in joint degree programs offered in partnership with the Medical School and Law School. Please reach out to program leadership if you would like to learn more about opportunities available to you through the MPaT graduate program!